Article
Extended Data Fig. 7 | CRISPR deletion of MCT1 from mouse melanoma cells
impairs metastasis, whereas MCT1 overexpression in patient-derived
xenografts increases metastasis. Related to Fig. 2. a, Western blot analysis of
MCT1 in wild-type parental YUMM1.7 melanoma cells as well as two lines from
which MCT1 had been deleted using CRISPR (KO #1 and #2). b–d, Growth of
subcutaneous tumours (b), total metastatic disease burden at end point by
bioluminescence imaging of visceral organs (c) and CellRox DeepRed staining
of subcutaneous tumour cells (d). The number of mice analysed in each
treatment is indicated (one experiment; note that one mouse died in the KO #2
treatment before end-point analysis). e, Western blot analysis of MCT1 in an
inefficiently metastasizing melanoma (UM47) expressing MCT1 cDNA.
f, g, Growth of subcutaneous tumours (f) and total metastatic disease burden
at end point by bioluminescence imaging of visceral organs (g) from mice
transplanted with these melanomas (one experiment; note that two mice died
in the control treatment before end-point analysis). Data are mean ± s.d.
Statistical significance was assessed using one-way ANOVA followed by
Dunnett’s multiple comparison adjustment (b, day 25) or log 2 -transformed
one-way ANOVAs followed by Dunnett’s multiple comparisons adjustment
(c, d), t-test (f, day 90) or log 2 -transformed t-test (g).